Citations

Clear

6 citation(s) found for "Nicholson, William".

Abstract 11505: Predicting In-Hospital All-Cause Mortality in Chronic Total Occlusion Percutaneous Coronary Intervention: PROGRESS-CTO Mortality Score
Karácsonyi, Judit , Göktekín, Ömer , Guindy, Ahmed El, Chandwaney, Raj, Patel, Mitul , Karmpaliotis, Dimitrios, Rangan, Bavana V. , Sandoval, Yader , Choi, James W. , Nicholson, William , Jaber, Wissam , Rinfret, Stéphane , KUTUZIS, MICHAEL, Yeh, Robert W. , Mastrodemos, Olga , Simsek, Bahadir , Kostantinis, Spyridon , Alaswad, Khaldoon , Krestyaninov, Oleg V. , Khelimskii, Dmitrii A. , Davies, Rhian E. , Görgülü, Şevket , Khatri, Jaikirshan J , Jaffer, Farouc A , KUTUZIS, MICHAEL, Tsiafoutis, Ioannis N. , Burke, M. Nicholas , Allana, Salman , Brilakis, Emmanouil S.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.11505 Get It

Introduction: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with increased risk of periprocedural complications. Estimating the risk of complications facilitates risk-benefit assessment and procedural planning. Methods: We analyzed the Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO, NCT02061436) and created a risk score for in-hospital all-cause mortality. Logistic regression prediction modeling was used to identify independently associated variables and the model was internally validated with bootstrapping. Results: Of the 10,480 CTO PCI cases performed between 2012-2022 at 40 US and non-US centers, in-hospital mortality occurred in 47 (0.45%). The final prediction model identified 4 independent predictors of mortality: Age ≥65 years, Odds Ratio [OR]: 2.83 (95% confidence interval [CI], 1.30-6.16), 1-point; Left ventricular ejection fraction ≤45%, OR: 2.13 (95% CI, 1.14-3.98), 1-point; Moderate-severe calcification, OR: 2.45 (95% CI, 1.18-5.08), 1-point; and Antegrade dissection re-entry, OR: 2.81 (95% CI, 1.06-7.43), 1-point; or Retrograde strategy, OR: 3.51 (95% CI, 1.67-7.37), 1-point; with a bootstrap corrected c-statistics of 0.71 (95% confidence interval: 0.63-0.81). The calculated risk percentages for mortality based on the PROGRESS-CTO mortality score ranged from 0.05-2.42% for mortality, and 63% of patients in the PROGRESS-CTO cohort had PROGRESS-CTO mortality score of 1 or 2, corresponding to a mortality risk of 0.1-0.5% (Figure 1). Conclusions: The PROGRESS-CTO in-hospital mortality risk score can facilitate risk-benefit assessment and procedural planning in patients undergoing CTO PCI.
Two‐Year Outcomes With a Next‐Generation Left Atrial Appendage Device: Final Results of the PINNACLE FLX Trial
Doshi, Shephal K. , Kar, Saibal , Sadhu, Ashish, Horton, Rodney , Osorio, José , Ellis, Christopher R. , Stone, James, Shah, Manish H. , Dukkipati, Srinivas R. , Adler, Stuart W., Kim, Jamie , Wazni, Oussama M. , Holmes, David R. , Shipley, Robert D., Christen, Thomas, Allocco, Dominic J. , Buchbinder, Maurice , Chinitz, Larry A. , Desai, Amish J., Dukkipatti, Srinivas R., Ellis, Christopher, Gibson, Douglas , Huber, Kenneth, Khairallah, Farhat, Koneru, Jayanthi N. , Mahoney, Paul G. , Mansour, Moussa , Mark, George E., Nicholson, William , REISS, J. A., Shehata, Michael , Swarup, Vijendra, Huber, Kurt , Téllez-Plaza, María , Ellis, Christopher , Shah, Manish , Nair, Devi G , Wazni, Oussama , Price, Matthew J , Holmes, David R , Reddy, Vivek Y , Kar, Saibal , Huber, Kurt , Price, Matthew J. , Reddy, Vivek Y. , DeLurgio, David B. , Ellis, Christopher, Huber, Kenneth, Mahoney, Paul, O’Neill, William W. , Reiss, James, Saliba, Walid I.

Mayo Clinic

Journal of the American Heart Association | February 21, 2023 | Volume: 12 | Issue: 4 | Pages: No page available

10.1161/jaha.122.026295 | PMID 36789852 Get It

Background The PINNACLE FLX (Protection Against Embolism for Non‐valvular AF [Atrial Fibrillation] Patients: Investigational Device Evaluation of the Watchman FLX LAA [Left Atrial Appendage] Closure Technology) trial evaluated the safety and efficacy of a next‐generation left atrial appendage closure device (WATCHMAN FLX; Boston Scientific, Marlborough, MA). At 1 year, the study met the primary end points of safety and anatomical efficacy/appendage closure. This final report of the PINNACLE FLX trial includes the prespecified secondary end point of ischemic stroke or systemic embolism at 2 years, also making it the first report of 2‐year outcomes with this next‐generation left atrial appendage closure device. Methods and Results Patients with nonvalvular atrial fibrillation with CHA 2 DS 2 ‐VASc score ≥2 (men) or ≥3 (women), with an appropriate rationale for left atrial appendage closure, were enrolled to receive the left atrial appendage closure device at 29 US centers. Adverse events were assessed by an independent clinical events committee, and imaging was assessed by independent core laboratories. Among 395 implanted patients (36% women; mean age, 74 years; CHA 2 DS 2 ‐VASc, 4.2±1.5), the secondary efficacy end point of 2‐year ischemic stroke or systemic embolism was met, with an absolute rate of 3.4% (annualized rate, 1.7%) and an upper 1‐sided 95% confidence bound of 5.3%, which was superior to the 8.7% performance goal. Two‐year rates of adverse events were as follows: 9.3% all‐cause mortality, 5.5% cardiovascular death, 3.4% all stroke, and 10.1% major bleeding (Bleeding Academic Research Consortium 3 or 5). There were no additional systemic embolisms, device embolizations, pericardial effusions, or symptomatic device‐related thrombi after 1 year. Conclusions The secondary end point of 2‐year stroke or systemic embolism was met at 3.4%. In these final results of the PINNACLE FLX trial, the next‐generation WATCHMAN FLX device demonstrated favorable safety and efficacy outcomes.
Impact of Active and Historical Cancers on the Management and Outcomes of Acute Myocardial Infarction Complicating Cardiogenic Shock
Patlolla, Sri Harsha , Bhat, Anusha Ganapati , Sundaragiri, Pranathi R., Cheungpasitporn, Wisit , Malleshappa, Sudeep K Siddappa , Pasupula, Deepak Kumar , Jaber, Wissam , Nicholson, William J. , Vallabhajosyula, Saraschandra , Cheungpasitporn, Wisit , Vallabhajosyula, Saraschandra , Harsha Patlolla, Sri , Doshi, Rajkumar

Mayo Clinic

Texas Heart Institute Journal | October 12, 2022 | Volume: 49 | Issue: 5 | Pages: No page available

10.14503/thij-21-7598 | PMID 36223249 Get It

Background There are limited data on the outcomes of acute myocardial infarction–cardiogenic shock (AMI-CS) in patients with concomitant cancer. Methods A retrospective cohort of adult AMI-CS admissions was identified from the National Inpatient Sample (2000–2017) and stratified by active cancer, historical cancer, and no cancer. Outcomes of interest included in-hospital mortality, use of coronary angiography, use of percutaneous coronary intervention, do-not-resuscitate status, palliative care use, hospitalization costs, and hospital length of stay. Results Of the 557,974 AMI-CS admissions during this 18-year period, active and historical cancers were noted in 14,826 (2.6%) and 27,073 (4.8%), respectively. From 2000 to 2017, there was a decline in active cancers (adjusted odds ratio, 0.70 [95% CI, 0.63–0.79]; P < .001) and an increase in historical cancer (adjusted odds ratio, 2.06 [95% CI, 1.89–2.25]; P < .001). Compared with patients with no cancer, patients with active and historical cancer received less-frequent coronary angiography (57%, 67%, and 70%, respectively) and percutaneous coronary intervention (40%, 47%, and 49%%, respectively) and had higher do-not-resuscitate status (13%, 15%, 7%%, respectively) and palliative care use (12%, 10%, 6%%, respectively) (P < .001). Compared with those without cancer, higher in-hospital mortality was found in admissions with active cancer (45.9% vs 37.0%; adjusted odds ratio, 1.29 [95% CI, 1.24–1.34]; P < .001) but not historical cancer (40.1% vs 37.0%; adjusted odds ratio, 1.01 [95% CI, 0.98–1.04]; P = .39). AMI-CS admissions with cancer had a shorter hospitalization duration and lower costs (all P < .001). Conclusion Concomitant cancer was associated with less use of guideline-directed procedures. Active, but not historical, cancer was associated with higher mortality in patients with AMI-CS.
Intravascular lithotripsy in chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS‐CTO registry
Kostantinis, Spyridon , Karácsonyi, Judit , Benton, Stewart M., Nicholson, William , Rinfret, Stéphane , Jaber, Wissam , Raj, Leah, Sandesara, Pratik B. , Basir, Mir B. , Young, Laura , Rafeh, Nidal Abi, Patel, Mitul , Kerrigan, Jimmy , Haddad, Elias V., Sandoval, Yader , Sheikh, Abdul Malik, ElGuindy, Ahmed , Göktekín, Ömer , Mastrodemos, Olga , Rangan, Bavana V. , Simsek, Bahadir , Sandesara, Pratik B , Basir, Mir B , Khatri, Jaikirshan J , Young, Laura D , Jaffer, Farouc A , Kerrigan, Jimmy L , Dattilo, Phil , Sandoval, Yader , Brilakis, Emmanouil S , Kostantinis, Spyridon , Megaly, Michael S. , Davies, Rhian E. , Alaswad, Khaldoon , Schimmel, Daniel R. , Burke, M. Nicholas , Brilakis, Emmanouil S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 2, 2022 | Volume: 100 | Issue: 4 | Pages: 512-519

10.1002/ccd.30354 | PMID 35916076 Get It

AbstractBackgroundThe use of intravascular lithotripsy (IVL) in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has received limited study.MethodsWe analyzed the baseline clinical and angiographic characteristics and procedural outcomes of 82 CTO PCIs that required IVL at 14 centers between 2020 and 2022.ResultsDuring the study period, IVL was used in 82 of 3301 (2.5%) CTO PCI procedures (0.4% in 2020 and 7% in 2022; p for trend < 0.001). Mean patient age was 69 ± 11 years and 79% were men. The prevalence of hypertension (95%), diabetes mellitus (62%), and prior PCI (61%) was high. The most common target vessel was the right coronary artery (54%), followed by the left circumflex (23%). The mean J‐CTO and PROGRESS‐CTO scores were 2.8 ± 1.1 and 1.3 ± 1.0, respectively. Antegrade wiring was the final successful crossing strategy in 65% and the retrograde approach was used in 22%. IVL was used in 10% of all heavily calcified lesions and 11% of all balloon undilatable lesions. The 3.5 mm lithotripsy balloon was the most commonly used balloon (28%). The mean number of pulses per lithotripsy run was 33 ± 32 and the median duration of lithotripsy was 80 (interquartile range: 40−103) seconds. Technical and procedural success was achieved in 77 (94%) and 74 (90%) cases, respectively. Two (2.4%) Ellis Class 2 perforations occurred after IVL use and were managed conservatively.ConclusionIVL is increasingly being used in CTO PCI with encouraging outcomes.
A Comprehensive Appraisal of Risk Prediction Models for Cardiogenic Shock
Bhat, Anusha Ganapati , Katz, Jason N. , Islam, Ashequl , Tehrani, Benham N., Truesdell, Alexander G. , Kapur, Navin K. , Holmes, David R. , Menon, Venugopal, Jaber, Wissam , Nicholson, William J. , Zhao, David , Vallabhajosyula, Saraschandra , Vallabhajosyula, Saraschandra , Diepen, Sean van

Mayo Clinic

Shock | May 18, 2022 | Volume: 57 | Issue: 5 | Pages: 617-629

10.1097/shk.0000000000001921 | PMID 35583910 Get It

ABSTRACT Despite advances in early revascularization, percutaneous hemodynamic support platforms, and systems of care, cardiogenic shock (CS) remains associated with a mortality rate higher than 50%. Several risk stratification models have been derived since the 1990 s to identify patients at high risk of adverse outcomes. Still, limited information is available on the differences between scoring systems and their relative applicability to both acute myocardial infarction and advanced decompensated heart failure CS. Thus, we reviewed the similarities, differences, and limitations of published CS risk prediction models and herein discuss their suitability to the contemporary management of CS care.
Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis — United States
Biggs, Holly M. , Behravesh, Casey Barton , Bradley, Kristy, Dahlgren, F. Scott , Drexler, Naomi A. , Dumler, J. Stephen , Folk, Scott M., Kato, Cecilia Y. , Lash, R. Ryan , Levin, Michael L. , Massung, Robert F., Nadelman, Robert B., Nicholson, William L. , Paddock, Christopher D., Pritt, Bobbi S. , Traeger, Marc, Paddock, Christopher D. , Pritt, Bobbi S

Mayo Clinic

MMWR. Recommendations and Reports | May 12, 2016 | Volume: 65 | Issue: 2 | Pages: 1-44

10.15585/mmwr.rr6502a1 | PMID 27172113 Get It